Navigation Links
Trovagene Announces Abstracts to be Presented at Molecular Targets and Cancer Therapeutics Conference
Date:10/19/2013

SAN DIEGO, Oct. 14, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that two abstracts (#B175 and #B177) highlighting results from studies of the company's novel, non-invasive cancer mutation monitoring platform will be presented on October 21, 2013 at the AACR-NCI-EORTC[1] International Conference on Molecular Targets and Cancer Therapeutics in Boston, MA.

(Logo: http://photos.prnewswire.com/prnh/20120620/LA28014LOGO)

Both studies were completed in collaboration with Dr. Filip Janku in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center in Houston. Trovagene is developing proprietary cell-free DNA urinary assays for molecular testing as a non-invasive alternative to mutation testing of tumor tissue.

The abstracts accepted for presentation during the "Molecular Classification of Tumors" poster session at the AACR-NCI-EORTC conference are:

Detection and monitoring of BRAF and KRAS mutations in cell-free urinary DNA of metastatic cancer patients by digital droplet PCR (Abstract #B175)

  • Monday, October 21, 12:30 – 3:00 p.m. and 6:30 – 7:30 p.m.
  • Location: Exhibit Hall C-D

Non-invasive tumor mutation detection of cell-free urinary DNA using massively parallel deep DNA sequencing (Abstract #B177)

  • Monday, October 21, 12:30 – 3:00 p.m. and 6:30 – 7:30 p.m.
  • Location: Exhibit Hall C-D

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is leveraging its patented technology for the detection of cell-free DNA and RNA, short nucleic acid fragments originating from normal and diseased cell death that can be isolated and detected from urine. Trovagene has a strong intellectual property asset as it relates to cell-free DNA and RNA testing in urine. It has U.S. and European patent applications and issued patents that cover testing for HPV and other infectious diseases, cancer, transplantation, prenatal and genetic testing.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on Trovagene's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or fourth party payer reimbursement; limited sales and marketing efforts and dependence upon fourth parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Trovagene's Form 10-K for the year ended December 31, 2012 and other periodic reports filed with the Securities and Exchange Commission.

Contact:
Amy Caterina
Trovagene, Inc.
Investor Relations
858-952-7593
acaterina@trovagene.com

[1] American Association for Cancer Research, National Cancer Institute and European Organisation for Research and Treatment of Cancer


'/>"/>
SOURCE Trovagene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Dr. Bradley Kurgis Announces Free Skin Rejuvenation Consultation
2. Extreme Peptide Announces that its EP Reward Points Program is Now Easier than Ever to Use
3. Prostate Cancer Foundation announces new urine test for prostate cancer available
4. EcoHealth Alliance announces new award from USAID to combat disease emergence and climate change
5. NIH announces awards to strengthen the biomedical research workforce
6. New York Genome Center announces the New York Stem Cell Foundation as an Associate Member
7. DiscoveRx Announces Launch of New Human Primary Cell-Based Panels for Oncology Research
8. Entomological Society of America announces 2013 awardees
9. Entomological Foundation announces 2013 Insect Science Award winners
10. Chair Mats of Glass Company Clearly Innovative Announces the Launch of 20 New Dealers in the Midwest
11. Diamond Vision Announces New and Generous Promotion on its iLASIK in NYC Procedure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/13/2018)... ... December 13, 2018 , ... Biocompare, the leading online ... “What Researchers Need to Know about Antibody Manufacturing” . This educational resource is ... goal of this film is to educate scientists about antibody production, validation, and ...
(Date:12/6/2018)... ... 2018 , ... Stewart has been on the business side ... career. During his recent five-year tenure with InSphero he was the US General ... operations in Brunswick, Maine. Through these experiences, Stewart has a deep understanding of ...
(Date:12/5/2018)... ... December 03, 2018 , ... uBiome, the leader ... professor in the Division of Gastroenterology and Hepatology at UC San Diego and ... Board. Joining the board of leading scientists and doctors from around the world, ...
Breaking Biology News(10 mins):
(Date:11/28/2018)... ... 28, 2018 , ... Earlier this month, Lajollacooks4u's Founder and Chef Jodi Abel ... height of truffle season. , Her first stop was Umbria, a region ... exclusive Black Truffle Lodge in the small mountain village of Pettino, Chef Jodi was ...
(Date:11/26/2018)... ... November 26, 2018 , ... USARAD Holdings Inc., the leading ... Partners (Virtual Radiologic founders) among other healthcare investors exhibits at the Radiological Society ... in Chicago. The company is proud to announce a 10 year anniversary since ...
(Date:11/20/2018)... Ga. (PRWEB) , ... November 19, 2018 , ... Patients ... receive custom dental implants from Dr. Dan Myers at THE DENTIST Centers ... dental implant placement and restorations for the last 20 years. He now offers skilled ...
(Date:11/20/2018)... ... November 20, 2018 , ... Dr. Steven White and Dr. ... at their office in Cornelius, NC. This common infection, left untreated, can be destructive ... along with special training and certification in laser dentistry, Drs. White and Haines are ...
Breaking Biology Technology: